Corporate Communications
Week ending August 30, 2026
1. This week’s narrative in one paragraph
AI assistants generally describe Cosentyx in a neutral, patient-oriented way: an IL-17A biologic that is effective for many people, with choice driven by diagnosis, individual response, dosing, tolerability, insurance, and patient preference. Answers repeatedly use shared-decision language such as “both are legitimate options” and advise against calling Cosentyx “stronger” or “better.” The main caution is that safety and label information is not consistently presented. Infection risk, candidiasis, inflammatory bowel disease, pregnancy, and monitoring appear frequently, while marketing-oriented answers also use competitive language such as “best,” “most effective,” “stronger,” and “leading.”
2. Anything with public-story potential
-
Conflicting answers about whether Cosentyx carries a boxed warning. In the safety question, five of six answer variants correctly say there is no boxed warning, while one says Cosentyx “carries a boxed warning” for serious infection. The public story would be: “AI assistants give conflicting answers about a major safety warning for Cosentyx.” This is the clearest holding-statement issue.
-
Inconsistent framing of pregnancy and infant vaccine questions. Answers vary between “use only if clearly needed,” “not recommended unless benefit outweighs risk,” and more reassuring descriptions of limited human data. The public story would be: “AI gives different answers to people asking whether Cosentyx is appropriate during pregnancy or breastfeeding.” This could attract patient-advocacy attention even though it is primarily a Medical Affairs/PV issue.
-
Confusion about substitution and access. Eleven responses mention generic or biosimilar concepts, and some imply Cosentyx may be replaced by a biosimilar, while others distinguish biosimilars from ordinary generics. The public story would be: “Patients cannot get a consistent answer about whether a pharmacy can substitute another product for Cosentyx.” No rise is evident, so this is monitor-only for now.
3. Topics with a public-attention history
Safety remains the historically sensitive area: infection risk appeared 75 times, and inflammatory bowel disease 32 times. There is no new spike, but these themes are prominent in comparisons with Humira, Stelara, Taltz, and Enbrel. Access and insurance are visible in switching discussions, but there is no evidence this week of a pricing or access narrative accelerating. Biosimilar/generic discussion is present but stable. Off-label discussion fell to zero, and no compounding signal is provided.
4. Trajectory
The overall narrative is stable, with fewer responses than last week but the same 20 questions. Most topic counts declined, including infection risk, overclaim language, and pregnancy. However, inconsistency flags increased from 26 to 29, the highest level in the available five-week history after the July baseline. The boxed-warning contradiction is recurring across the dataset rather than a new trend.
5. Recommended actions
- Prepare a short holding statement on the boxed-warning contradiction, pending label confirmation with Regulatory/Medical Affairs; this is most likely to become a screenshot-driven story.
- Prepare aligned talking points for pregnancy, breastfeeding, and infant vaccine questions, with Medical Affairs/PV, in case an advocacy group surfaces inconsistent AI answers.
- Monitor substitution/biosimilar language; no proactive response yet, but confirm the public-facing access position with Market Access/Regulatory.
- Continue weekly monitoring of safety and competitor comparisons; current framing is mostly balanced, so no broader communications intervention is warranted.